Retrospective study of the associations between hepatitis C virus infection and metabolic factors

Table 5 Unadjusted (model 1) and adjusted (model 2) logistic regression analyses of the association between the response to hepatitis C antiviral treatment and the de novo occurrence of metabolic syndrome components

Variable	Model 1			Model 2
	n	OR	95%CI (P value)	n	OR	95%CI (P value)
T2DM (diagnosis, fasting blood glucose > 126 mg/dL, or use of anti-diabetic drugs)	83	5.07	1.261-20.494 (0.022)	-
IFG (fasting blood glucose > 100 mg/dL)	83	3.87	1.484-10.154 (0.006)	53	4.71	1.280-17.316 (0.020)
Hypertriglyceridemia (triglycerides > 150 mg/dL)	96	0.27	0.069-0.967 (0.044)	-
Low HDL levels	54	0.70	0.188-2.607 (0.595)	39	1.5241	0.185-12.588 (0.695)
Men: HDL ≤ 35 mg/dL						-
Women: HDL ≤ 39 mg/dL
Obesity (BMI > 30 kg/m2)	96	1.12	0.178-7.030 (0.91)	96	0.782	0.115-5.339 (0.80)
Hypertension (defined by WHO)	95	1.176	0.379-3.626 (0.782)	62	1.921	0.246-5.636 (0.458)
Hepatic steatosis determined by ultrasound	90	2.66	0.929-7.636 (0.068)	64	2.1511	0.555-8.33 (0.268)

¹Adjusted for sex, age, and BMI;

²Adjusted for sex, age, and genotype. The responders group is the reference group for all the dependent variables. Multivariable analysis could not be conducted owing to the small number of responders with de novo DM (n = 3) or small number of non-responders with hypertriglyceridemia (n = 3). OR: Odds ratio; BMI: Body mass index; IFG: Impaired fasting glucose; T2DM: Type 2 diabetes mellitus; HDL: High-density lipoprotein cholesterol; WHO: World Health Organization; DM: Diabetes mellitus.